HC Wainwright reissued their buy rating on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) in a research note issued to investors on Thursday, Benzinga reports. The firm currently has a $60.00 price target on the stock. A number of other equities analysts also recently weighed in on the company. JMP Securities reiterated a market […]
Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price target increased by Morgan Stanley from $50.00 to $70.00 in a research note released on Thursday, Benzinga reports. They currently have an overweight rating on the stock. Other analysts also recently issued research reports about the stock. Robert W. Baird raised their price target on shares […]
Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its target price boosted by Robert W. Baird from $52.00 to $62.00 in a research report sent to investors on Thursday morning, Benzinga reports. The brokerage currently has an outperform rating on the stock. Several other equities research analysts also recently weighed in on CRNX. Morgan Stanley upped […]
HC Wainwright Reiterates "Buy" Rating for Crinetics Pharmaceuticals (NASDAQ:CRNX) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Lisanti Capital Growth LLC boosted its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 100.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 100,245 shares of the company’s stock after acquiring an additional 50,265 shares during the period. Lisanti Capital […]